var data={"title":"Ibuprofen: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ibuprofen: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6351?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">see &quot;Ibuprofen: Drug information&quot;</a> and <a href=\"topic.htm?path=ibuprofen-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ibuprofen: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708913\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiovascular thrombotic events (excluding NeoProfen):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ibuprofen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious gastrointestinal bleeding, ulcerations, and perforation (excluding NeoProfen):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI  bleeding are at greater risk for serious GI events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181456\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Addaprin [OTC];</li>\n      <li>Advil Junior Strength [OTC];</li>\n      <li>Advil Migraine [OTC];</li>\n      <li>Advil [OTC];</li>\n      <li>Caldolor;</li>\n      <li>Childrens Advil [OTC];</li>\n      <li>Childrens Motrin Jr Strength [OTC] [DSC];</li>\n      <li>Childrens Motrin [OTC];</li>\n      <li>Dyspel [OTC];</li>\n      <li>Genpril [OTC];</li>\n      <li>GoodSense Ibuprofen Childrens [OTC];</li>\n      <li>GoodSense Ibuprofen [OTC];</li>\n      <li>I-Prin [OTC];</li>\n      <li>IBU;</li>\n      <li>IBU-200 [OTC];</li>\n      <li>Ibuprofen Childrens [OTC];</li>\n      <li>Ibuprofen Comfort Pac;</li>\n      <li>Infants Advil [OTC];</li>\n      <li>KS Ibuprofen [OTC];</li>\n      <li>Motrin IB [OTC];</li>\n      <li>Motrin Infants Drops [OTC];</li>\n      <li>Motrin Junior Strength [OTC] [DSC];</li>\n      <li>Motrin [OTC] [DSC];</li>\n      <li>NeoProfen;</li>\n      <li>Provil [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181457\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advil;</li>\n      <li>Advil Pediatric Drops;</li>\n      <li>Caldolor;</li>\n      <li>Children&rsquo;s Advil;</li>\n      <li>Children&rsquo;s Europrofen;</li>\n      <li>Ibuprofen Muscle and Joint;</li>\n      <li>Motrin;</li>\n      <li>Motrin (Children's);</li>\n      <li>Motrin IB;</li>\n      <li>Pamprin Ibuprofen Formula;</li>\n      <li>Super Strength Motrin IB Liquid Gel Capsules</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053332\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Nonopioid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antipyretic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442611\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Oral liquid products are available in two concentrations (ie, concentrated infant drops: 50 mg/1.25 mL and suspension: 100 mg/5 mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as &quot;mg&quot;.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>PDA closure: Note:</b> Use birth weight to calculate all doses; monitor urine output; a decrease in urine output may require dose adjustment or holding of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Ibuprofen lysine (NeoProfen): GA &le;32 weeks weighing 500 to 1,500 g at birth: Initial dose: 10 mg/kg, followed by two doses of 5 mg/kg/dose at 24 and 48 hours after the initial dose. A second course of treatment, alternative pharmacologic therapy, or surgery may be needed if the ductus arteriosus fails to close or reopens following the initial course of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Ibuprofen lysine: Reported dosing approach variable (standard or high-dose therapy):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Standard-dose therapy: Limited data available: GA &gt;32 weeks: Initial dose: 10 mg/kg, followed by two doses of 5 mg/kg/dose administered at 24 hour intervals (Hirt 2008; Mei&szlig;ner 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-dose therapy: Limited data available: GA 24 to &lt;40 weeks: Initial dose: 20 mg/kg, followed by two doses of 10 mg/kg/dose administered at 24-hour intervals has been evaluated in a total of 58 neonates in two studies (GA: 24 to 39 weeks, PNA &le;5 days for majority of patients). In comparison to the standard dose, these studies found a higher rate of PDA closure using high dose therapy without an increase in adverse effects (Dani 2012; Mei&szlig;ner 2012). Pharmacokinetic data suggest that clearance increases with postnatal age; therefore, doses at the higher end of the dosage range may be necessary in older neonates (Hirt 2008; Van Overmeire 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Limited data available: GA &lt;34 weeks weighing &lt;1500 g at birth: Initial dose: 10 mg/kg, followed by two doses of 5 mg/kg/dose at 24 and 48 hours after the initial dose; doses were administered undiluted through a feeding tube and immediately followed with a flush (~1 mL) of distilled water; this dosing regimen has been used in several trials and has been shown to be safe and as effective as IV ibuprofen and IV indomethacin (Erdeve 2012; Heyman 2003; Lee 2012); in one retrospective study, oral ibuprofen (n=52) was associated with lower rates of elevated serum creatinine compared to IV indomethacin (n=88) (Lee 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> IV: Ibuprofen lysine (Neoprofen): If anuria or marked oliguria (urinary output &lt;0.6 mL/kg/hour) is evident at the scheduled time of the second or third dose, hold dose until renal function returns to normal. Use is contraindicated in preterm infants with significant renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053326\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">see &quot;Ibuprofen: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time to achieve treatment goals:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Oral liquid products are available in two concentrations (ie, concentrated infant drops: 50 mg/1.25 mL and suspension: 100 mg/5 mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as &quot;mg&quot;.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesic: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Ibuprofen injection (Caldolor): <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 6 months to Children &lt;12 years: 10 mg/kg/dose (maximum dose: 400 mg/dose) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/<b>day</b> or 2,400 mg/<b>day</b>, whichever is less</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 12 to 17 years: 400 mg every 4 to 6 hours as needed; maximum daily dose: 2,400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Infants and Children &lt;50 kg: Limited data available in infants &lt;6 months: 4 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/<b>day</b> (APS 2008; Berde 1990; Berde 2002; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children 6 months to 11 years: See table based upon manufacturer's labeling; use of weight to select dose is preferred; if weight is not available, then use age; doses may be repeated every 6 to 8 hours; maximum: 4 doses/day; treatment of sore throat for &gt;2 days or use in infants and children &lt;3 years of age with sore throat is not recommended, unless directed by health care provider.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Ibuprofen Dosing</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Weight (preferred)<sup>A</sup></p></th>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dosage</p>\n            <p style=\"text-indent:0em;\">(mg)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">kg</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">lbs</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.4 to 8.1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 11 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.2 to 10.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18 to 23</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 23 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.9 to 16.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">24 to 35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16.4 to 21.7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">36 to 47</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 5 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">21.8 to 27.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">48 to 59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 8 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">27.3 to 32.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 71</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 to 10 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">32.7 to 43.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">72 to 95</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Manufacturer's recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg.</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;12 years and Adolescents: Oral: 200 mg every 4 to 6 hours as needed; if pain does not respond may increase to 400 mg; maximum daily dose: 1,200 mg/<b>day</b>; treatment of pain for &gt;10 days is not recommended, unless directed by health care provider</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antipyretic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Ibuprofen injection (Caldolor): <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 6 months to Children &lt;12 years: 10 mg/kg/dose (maximum dose: 400 mg/dose) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/<b>day</b> or 2,400 mg/<b>day</b>, whichever is less</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 12 to 17 years: 400 mg every 4 to 6 hours as needed; maximum daily dose: 2,400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Infants &ge;6 months, Children, and Adolescents: 5 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/<b>day</b> up to 1,200 mg, unless directed by physician; under physician supervision daily doses &le;2,400 mg may be used (Kliegman 2011; Litalien 2001; Sullivan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children 6 months to 11 years: Oral: See table based upon manufacturer's labeling; use of weight to select dose is preferred; if weight is not available, then use age; doses may be repeated every 6 to 8 hours; maximum: 4 doses/day; treatment for &gt;3 days is not recommended unless directed by health care provider</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Weight (preferred)<sup>A</sup></p></th>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dosage</p>\n            <p style=\"text-indent:0em;\">(mg)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">kg</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">lbs</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.4 to 8.1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 11 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.2 to 10.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18 to 23</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 23 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.9 to 16.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">24 to 35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16.4 to 21.7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">36 to 47</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 5 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">21.8 to 27.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">48 to 59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 8 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">27.3 to 32.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 71</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 to 10 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">32.7 to 43.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">72 to 95</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Manufacturer's recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg.</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, mild disease (to slow lung disease progression): </b> Limited data available: Children and Adolescents 6 to 17 years with FEV<sub>1</sub> &gt;60% predicted (Mogayzel 2013): Oral: Initial: 20 to 30 mg/kg/dose twice daily; titrate to achieve peak plasma concentrations of 50 to 100 mcg/mL; should not eat or take pancreatic enzymes for 2 hours after the ibuprofen dose. Dosing based on a study of 41 patients (ages: 5 to 39 years); mean required dose: ~25 mg/kg/dose twice daily, reported range: 16.2 to 31.6 mg/kg/dose every 12 hours required to achieve target concentration; results showed that chronic ibuprofen use (over 4 years) slowed the rate of decline in FEV<sub>1</sub>; patients 5 to 13 years old with mild lung disease were observed to have greatest benefit; (Konstan 1995). A follow up observational study (n=1,365; ages: 6 to 17 years) under noncontrolled conditions (real world) showed significant improvement in the rate of decline of lung disease progression with chronic ibuprofen therapy (Konstan 2007). <b>Note:</b> Timing of blood sampling postdose is based on dosage form: Oral suspension: Obtain blood samples at 30, 45, and 60 minutes postdose; tablets: Obtain blood samples at 1, 2, and 3 hours postdose (Litalien 2001; Scott 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis (JIA):</b> Children and Adolescents: Usual range: 30 to 40 mg/kg/<b>day</b> in 3 to 4 divided doses; start at lower end of dosing range and titrate; patients with milder disease may be treated with 20 mg/kg/<b>day</b>; patients with more severe disease may require up to 50 mg/kg/<b>day</b>; maximum single dose: 800 mg; maximum daily dose: 2,400 mg/<b>day</b> (Giannini 1990; Kliegman 2011; Litalien 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia/pain/dysmenorrhea:</b> Oral: 400 mg/dose every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesic:</b> IV (Caldolor): 400 to 800 mg every 6 hours as needed; maximum daily dose: 3,200 mg/<b>day</b>. <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antipyretic:</b> IV (Caldolor): Initial: 400 mg, then 400 mg every 4 to 6 hours or 100 to 200 mg every 4 hours as needed; maximum daily dose: 3,200 mg/<b>day</b>. <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoarthritis, rheumatoid arthritis:</b> Oral: 400 to 800 mg 3 to 4 times daily (maximum: 3,200 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>OTC labeling: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Analgesia/Antipyretic:</b> Oral: 200 mg every 4 to 6 hours as needed; if no relief may increase to 400 mg every 4 to 6 hours as needed; maximum daily dose: 1,200 mg/24 hours; treatment for &gt;10 days as an analgesic or &gt;3 days as an antipyretic is not recommended unless directed by health care provider</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Migraine:</b> Oral: 400 mg at onset of symptoms; maximum daily dose: 400 mg/24 hours unless directed by health care provider</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling; avoid use in advanced disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">KDIGO 2012 guidelines provide the following recommendations for NSAIDs: Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Avoid use in patients with intercurrent disease that increases risk of acute kidney injury</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use caution and discontinue if hepatic function worsens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181430\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil Migraine: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen: 200 mg [gluten free; contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">KS Ibuprofen: 200 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen Comfort Pac: 800 mg [contains methylparaben, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caldolor: 400 mg/4 mL (4 mL [DSC]); 800 mg/8 mL (8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as lysine [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NeoProfen: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [contains edetate disodium, fd&amp;c red #40, polysorbate 80, propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; contains brilliant blue fcf (fd&amp;c blue #1), edetate disodium, fd&amp;c red #40, polysorbate 80, propylene glycol, sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; contains brilliant blue fcf (fd&amp;c blue #1), propylene glycol, sodium benzoate; blue raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (30 mL, 120 mL) [alcohol free, dye free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c blue #1 aluminum lake, fd&amp;c red #40, polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (60 mL [DSC]) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), polysorbate 80, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL [DSC]) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40, polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL [DSC]) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free, dye free; contains polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL [DSC]) [alcohol free, dye free; contains sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen Childrens: 100 mg/5 mL (120 mL) [alcohol free, dye free, gluten free; contains polysorbate 80, sodium benzoate, sorbitol; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen Childrens: 100 mg/5 mL (118 mL) [alcohol free; contains corn starch, fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), polysorbate 80, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen Childrens: 100 mg/5 mL (118 mL) [alcohol free; contains corn starch, fd&amp;c red #40, polysorbate 80, sodium benzoate; bubble-gum flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants Advil: 50 mg/1.25 mL (30 mL) [alcohol free, dye free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants Advil: 50 mg/1.25 mL (15 mL) [alcohol free, dye free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin: 40 mg/mL (15 mL [DSC]) [alcohol free, dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL [DSC]) [contains fd&amp;c red #40, polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [contains fd&amp;c red #40, polysorbate 80, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [alcohol free; contains fd&amp;c red #40, polysorbate 80, sodium benzoate, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [alcohol free; contains fd&amp;c red #40, polysorbate 80, sodium benzoate, sorbitol; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL [DSC], 30 mL) [alcohol free, dye free; contains polysorbate 80, sodium benzoate, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (5 mL, 118 mL, 120 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Addaprin: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil: 200 mg [contains methylparaben, propylparaben, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil Junior Strength: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dyspel: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genpril: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen: 200 mg [gluten free; contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen: 200 mg [gluten free; contains corn starch, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">I-Prin: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IBU-200: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IBU: 400 mg, 600 mg, 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin IB: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin IB: 200 mg [contains corn starch, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin IB: 200 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Junior Strength: 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg, 400 mg, 600 mg, 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil Junior Strength: 100 mg [scored; contains aspartame, fd&amp;c blue #2 aluminum lake; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 50 mg [DSC] [contains aspartame, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin Jr Strength: 100 mg [DSC] [contains aspartame, brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Junior Strength: 100 mg [DSC] [contains aspartame, brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Junior Strength: 100 mg [DSC] [contains aspartame, fd&amp;c yellow #6 (sunset yellow)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181416\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23884416\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">see &quot;Ibuprofen: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">EnovaRX-Ibuprofen cream is compounded from a kit. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874617\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg==&amp;TOPIC_ID=13371\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053337\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with food or milk to decrease GI upset; shake suspension well before use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ibuprofen injection (Caldolor): For IV administration only; in pediatric patients, infuse over at least 10 minutes; in adults, infuse dose over at least 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ibuprofen lysine injection (NeoProfen): For IV administration only; administration via umbilical arterial line has not been evaluated. Infuse over 15 minutes through IV port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed, interrupt TPN for 15 minutes prior to and after ibuprofen administration, keeping line open with dextrose or saline.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2985480\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ibuprofen injection (Caldolor): Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Must be diluted prior to use. Diluted solutions are stable in D5W, LR, or NS for 24 hours at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ibuprofen lysine injection (NeoProfen): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light. Store vials in carton until use. After first withdrawal from vial, discard remaining solution (preservative free). Following dilution in D5W or NS, use within 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053336\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OTC products: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infant drops, suspension, and chewable tablets: Relief of minor aches and pains due to the common cold, flu, sore throat, headaches, and toothaches; reduction of fever (All indications: OTC products: FDA approved in ages 6 months to 11 years; consult specific product formulation for appropriate age group)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule/Tablet: Relief of minor aches and pains due to the common cold, headaches, minor pain of arthritis, backache, menstrual cramps, muscle aches, and toothaches (All indications: OTC products: FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule (Advil Migraine): Treatment of migraines (OTC products: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prescription strength (400, 600, and 800 mg tablets): Relief of mild to moderate pain; relief of signs and symptoms of osteoarthritis and rheumatoid arthritis; treatment of primary dysmenorrhea (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral ibuprofen has also been used for juvenile idiopathic arthritis (JIA), cystic fibrosis, migraine pain,  gout, and for PDA closure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ibuprofen injection (Caldolor): Management of mild to moderate pain, management of moderate to severe pain when used concurrently with an opioid analgesic, reduction of fever (All indications: FDA approved in ages &ge;6 months and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ibuprofen lysine injection (NeoProfen): Treatment (ie, closure) of a clinically significant PDA when usual treatments are ineffective (FDA approved in premature neonates &le;32 weeks gestational age and weighing 500 to 1,500 g). <b>Note:</b> The prophylactic use of ibuprofen is not currently indicated nor recommended (Ohlsson 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181516\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-left:2em;\">Haltran may be confused with Halfprin</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Motrin may be confused with Neurontin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Ibuprofen is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). May increase risk of acute kidney injury and further decline of kidney function in elderly patients with stages IV or higher chronic kidney disease or CrCl less than 30 mL/minute (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Injectable formulations: Both ibuprofen and ibuprofen lysine are available for parenteral use. Ibuprofen lysine is <b>only</b> indicated for closure of a clinically-significant patent ductus arteriosus.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181514\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, dyspepsia, epigastric pain, flatulence, heartburn, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Abnormal hepatic function tests, acute renal failure, agranulocytosis, allergic rhinitis, alopecia, amblyopia, anaphylaxis, aplastic anemia, aseptic meningitis, azotemia, blurred vision, bone marrow depression, bronchospasm, cardiac arrhythmia, cardiac failure, confusion, conjunctivitis, cystitis, decreased creatinine clearance, decreased hematocrit, decreased hemoglobin, decreased platelet aggregation, depression, drowsiness, dry eye syndrome, duodenal ulcer, emotional lability, eosinophilia, epistaxis, erythema multiforme, gastric ulcer, gastritis, gastrointestinal hemorrhage, gastrointestinal ulcer, hallucination, hearing loss, hematuria, hemolytic anemia, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypertension, insomnia, jaundice, leukopenia, melena, neutropenia, palpitations, pancreatitis, peripheral neuropathy, polydipsia, polyuria, skin photosensitivity, Stevens-Johnson syndrome, tachycardia, thrombocytopenia, toxic amblyopia, toxic epidermal necrolysis, urticaria, vesiculobullous dermatitis, vision changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection: Ibuprofen (Caldolor):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema, hypertension (including exacerbation), myocardial infarction, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Exfoliative dermatitis, pruritus, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Changes in LDH, hypernatremia, hypoalbuminemia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal discomfort, Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Renal toxicity, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, decreased hemoglobin, eosinophilia, hemorrhage, hypoproteinemia, neutropenia, thrombocythemia, wound hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bacterial pneumonia, cough</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection: Ibuprofen lysine (NeoProfen):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure, edema, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Convulsions, eating disorder, intraventricular hemorrhage, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin lesion, skin irritation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Adrenocortical insufficiency, hyperglycemia, hypernatremia, hypocalcemia, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distension, cholestasis, enterocolitis, gastritis, gastroesophageal reflux disease, gastrointestinal disease (non-NEC), inguinal hernia, intestinal obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Decreased urine output (small decrease reported on days 2 to 6 with compensatory increase in output on day 9), uremia, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, atelectasis, respiratory failure, respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Reduced intake of food/fluids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Gastrointestinal perforation, hepatotoxicity (idiosyncratic) (Chalasani 2014), necrotizing enterocolitis, pulmonary hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181438\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ibuprofen (eg, anaphylactic reactions, serious skin reactions) or any component of the formulation; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; aspirin triad (eg, bronchial asthma, aspirin intolerance, rhinitis); use in the setting of coronary artery bypass graft (CABG) surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibuprofen lysine (NeoProfen): Preterm neonates: With proven or suspected infection that is untreated; congenital heart disease in whom patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow (eg, pulmonary atresia, severe coarctation of the aorta, severe tetralogy of Fallot); bleeding (especially those with active intracranial hemorrhage or GI bleeding); thrombocytopenia; coagulation defects; proven or suspected necrotizing enterocolitis; or significant renal function impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Cerebrovascular bleeding or other bleeding disorders; active gastric/duodenal/peptic ulcer, active GI bleeding; inflammatory bowel disease; uncontrolled heart failure; moderate [IV formulation only] to severe renal impairment (creatinine clearance [CrCl] &lt;30 mL/minute); deteriorating renal disease; moderate [IV formulation only] to severe hepatic impairment; active hepatic disease; hyperkalemia; third trimester of pregnancy; breast-feeding; patients &lt;18 years of age [IV formulation only]; patients &lt;12 years of age [oral formulation only]; systemic lupus erythematosus [oral formulation only]; children suffering from dehydration as a result of acute diarrhea, vomiting, or lack of fluid intake</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">OTC labeling: When used for self-medication, do not use if previous allergic reaction to any other pain reliever/fever reducer; prior to or following cardiac surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181420\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events:<b> [US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including fatal MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of cardiovascular events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors. New-onset hypertension or exacerbation of hypertension may occur (NSAIDS may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention; use with caution in patients with edema. Avoid use in heart failure (ACCF/AHA [Yancy 2013]). Avoid use in patients with a recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events: <b>[US Boxed Warning]: NSAIDs cause an increased risk of serious gastrointestinal inflammation, ulceration, bleeding, and perforation (may be fatal); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. In patients with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis (Strate 2016). Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare (sometimes fatal) severe hepatic reactions (eg, fulminant hepatitis, liver necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if signs or symptoms of hepatic disease develop or if systemic manifestations occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic events: Blurred/diminished vision, scotomata, and changes in color vision have been reported. Discontinue therapy and refer for ophthalmologic evaluation if symptoms occur. Periodically evaluate vision in all patients receiving long-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis and other renal injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: NSAIDs may cause potentially fatal serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery bypass graft surgery: <b>[US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with advanced renal disease; discontinue use with persistent or worsening abnormal renal function tests. Use of ibuprofen lysine (NeoProfen) is contraindicated in preterm infants with significant renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are at greater risk for serious GI events; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ibuprofen injection (Caldolor): Must be diluted prior to administration; hemolysis can occur if not diluted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ibuprofen lysine injection (NeoProfen): Hold second or third doses if urinary output is &lt;0.6 mL/kg/hour. May alter signs of infection. May inhibit platelet aggregation; monitor for signs of bleeding. May displace bilirubin; use caution when total bilirubin is elevated. Long-term evaluations of neurodevelopment, growth, or diseases associated with prematurity following treatment have not been conducted. A second course of treatment, alternative pharmacologic therapy or surgery may be needed if the ductus arteriosus fails to close or reopens following the initial course of therapy. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self medication (OTC use): Prior to self-medication, patients should contact health care provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, or are &ge;60 years of age. If patients are using for migraines, they should also contact health care provider if they have not had a migraine diagnosis by health care provider, a headache that is different from usual migraine, worst headache of life, fever and neck stiffness, headache from head injury or coughing, first headache at &ge;50 years of age, daily headache, or migraine requiring bed rest. Recommended dosages should not be exceeded, due to an increased risk of GI bleeding. Stop use and consult a health care provider if symptoms do not improve within first 24 hours of use (children) get worse, or newly appear, fever lasts for &gt;3 days or pain lasts &gt;3 days (children) and &gt;10 days (adults). Do not give for &gt;10 days unless instructed by healthcare provider. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023241\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oral liquid products are available in two concentrations (ie, concentrated infant drops: 50 mg/1.25 mL and suspension: 100 mg/5 mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as &quot;mg&quot;.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A single-center, 10-year, retrospective review of pediatric patients diagnosed with acute kidney injury (AKI) (n=1,015; ages: &le;18 years) reported NSAIDS as a potential cause of AKI in 2.7% of patients (n=27); a higher incidence (6.6%) was reported when additional exclusion factors were included in the data analysis. Dosing information was available for 74% of the NSAID-associated AKI cases (n=20); dosing was within the recommended range in 75% (n=15) of these cases. The median age of children with NSAID-associated AKI was 14.7 years (range: 0.5 to 17.7 years) and 15% of patients were &lt;5 years and more likely to require dialysis than the older patients. Some experts suggest the incidence of NSAID-associated AKI found in this study is conservative due to aggressive exclusion criteria (eg, concurrent aminoglycoside or other nephrotoxic therapy) and the actual incidence may be higher (Brophy 2013; Misurac 2013). IV ibuprofen is as effective as IV indomethacin for the treatment of PDA in preterm neonates, but is less likely to cause adverse effects on renal function (eg, oliguria, increased serum creatinine) (Aranda 2006; Lago 2002; Ohlsson 2013; Van Overmeire 2000). Ibuprofen (compared to indomethacin) also has been shown to decrease the risk of developing NEC (Ohlsson 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In neonates, pulmonary hypertension has occurred following use for treatment of PDA; ten cases have been reported; three following early (prophylactic) administration of tromethamine ibuprofen (not available in US) and seven cases following L-lysine ibuprofen therapy (Bellini 2006; Gournay 2002; Ohlsson 2013). Avoid extravasation of ibuprofen lysine injection (NeoProfen); IV solution may be irritating to tissues. Use with caution in neonates with controlled infection or those at risk for infection; ibuprofen may alter the usual signs of infection. Use with caution in neonates when total bilirubin is elevated; ibuprofen may displace bilirubin from albumin-binding sites. Intraventricular hemorrhage has been reported; overall incidence: 29%; grade 3/4: 15%. Long-term evaluations of neurodevelopmental outcome, growth, or diseases associated with prematurity (eg, chronic lung disease, retinopathy of prematurity) following treatment have not been conducted.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181500\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181425\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13371&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs).  Avoid the use of diclofenac/misoprostol with other NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelubiprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PEMEtrexed: Ibuprofen may increase the serum concentration of PEMEtrexed.  Management: In patients with an estimated creatinine clearance of 45 to 79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed. Monitor for increased pemetrexed toxicities if combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b> Exceptions: </b>Choline Magnesium Trisalicylate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaltoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181452\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ibuprofen peak serum levels may be decreased if taken with food. Management: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7684272\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because NSAIDs cause premature closure of the ductus arteriosus, prescribing information for ibuprofen specifically states use should be avoided starting at 30-weeks gestation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of NSAIDs can be considered for the treatment of mild rheumatoid arthritis flares in pregnant women; however, use should be minimized or avoided early and late in pregnancy (Bermas 2014; Saavedra Salinas 2015). If treatment of migraine is needed in pregnant women, ibuprofen is preferred when an NSAID is required; however, other agents are recommended as initial therapy (Amundsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in women having difficulty conceiving or those undergoing investigation of fertility. The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bloor 2013; Bermas 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053331\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, serum electrolytes, occult blood loss, liver enzymes; urine output, serum BUN, and creatinine in patients receiving IV ibuprofen, concurrent diuretics, those with decreased renal function, or in patients on chronic therapy. Monitor preterm neonates for signs of bleeding and infection; serum electrolytes, glucose, calcium and bilirubin; vital signs; monitor IV site for signs of extravasation. Patients receiving long-term therapy for JIA should receive periodic ophthalmological exams.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053335\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma concentrations &gt;200 mcg/mL may be associated with severe toxicity; cystic fibrosis: therapeutic peak plasma concentration: 50 to 100 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181419\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181437\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: Analgesic: Within 30 to 60 minutes (Davies 1998; Mehlisch 2013); Antipyretic: Single oral dose 8 mg/kg (Kauffman 1992): Infants &le;1 year: 69 &plusmn; 22 minutes; Children &ge;6 years: Single oral dose 8 mg/kg (Kauffman 1992): 109 &plusmn; 64 minutes; Adults: &lt;1 hour (Sullivan 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: Antipyretic: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: Antipyretic: 6 to 8 hours (Sullivan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid (85%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Febrile children &lt;11 years: 0.2 L/kg; Adults: 0.12 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Ibuprofen (Caldolor):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients 6 months to &lt;2 years: 0.31 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients 2 to 16 years: 0.23 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Ibuprofen lysine: Premature neonates, GA &lt;32 weeks: Variable results observed: 0.32 L/kg, others have reported: a central compartment Vd that decreases with increasing PNA and ductal closure (Van Overmeire, 2001) and a  V<sub>d</sub>, apparent: 0.062 L/kg in 21 premature neonates (GA &lt;32 weeks, PNA: &lt;1 day) (Aranda 1997); a 2-compartment open model was observed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99%; Premature infants: ~95% (Aranda 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via oxidation; <b>Note:</b> Ibuprofen is a racemic mixture of R and S isomers; the R isomer (thought to be inactive) is slowly and incompletely (~60%) converted to the S isomer (active) in adults; the amount of conversion in children is not known, but it is thought to be similar to adults; a study in preterm neonates estimated the conversion to be 61% after prophylactic ibuprofen use and 86% after curative treatment (Gregoire 2004).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen (Caldor): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients: 6 months to &lt;2 years: 1.8 hours; 2 to 16 years: ~1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 2.22 to 2.44 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen lysine (Neoprofen):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Premature neonates, GA &lt;32 weeks: Reported data highly variable</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">R-enantiomer: 10 hours; S-enantiomer: 25.5 hours (Gregoire 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Age-based observations:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">PNA &lt;1 day: 30.5 &plusmn; 4.2 hours (Aranda 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">PNA 3 days: 43.1 &plusmn; 26.1 hours (Van Overmeire 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">PNA 5 days: 26.8 &plusmn; 23.6 hours (Van Overmeire 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 3 months to 10 years: Oral suspension: 1.6 &plusmn; 0.7 hours (Kauffman 1992) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~2 hours; End-stage renal disease: Unchanged (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Tablets: 1 to 2 hours; Suspension: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with cystic fibrosis (Scott 1999): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Suspension (n=22): 0.74 &plusmn; 0.43 hours (median: 30 minutes) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Chewable tablet (n=4): 1.5 &plusmn; 0.58 hours (median: 1.5 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet (n=12): 1.33 &plusmn; 0.95 hours (median: 1 hour) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as metabolites (45% to 80%); ~1% as unchanged drug and 14% as conjugated); some feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053342\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Motrin suspension contains sucrose 0.3 g/mL and 1.6 calories/mL. Due to its effects on platelet function, ibuprofen should be withheld for at least 4 to 6 half-lives prior to surgical or dental procedures.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">There is currently no scientific evidence to support alternating acetaminophen with ibuprofen in the treatment of fever (Mayoral 2000) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181440\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Advil Migraine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (40): $6.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (2): $0.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ibuprofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (80): $6.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Advil Junior Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (24): $4.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Ibuprofen Comfort Pac Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (1): $74.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caldolor Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg/8 mL (8 mL): $19.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ibuprofen Lysine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $487.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NeoProfen Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $732.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Childrens Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (120 mL): $5.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Childrens Motrin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (120 mL): $6.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Ibuprofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $0.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Infants Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/1.25 mL (15 mL): $4.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Motrin Infants Drops Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/1.25 mL (15 mL): $5.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Advil Junior Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (24): $4.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (200): $16.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (IBU Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $20.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (90): $26.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (90): $34.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ibuprofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $5.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (500): $170.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $51.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $80.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Motrin IB Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (50): $5.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Provil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (50): $3.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181443\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actiprofen (IE);</li>\n      <li>Actron (CR, DO, GT, HN, NI, PA, PY, SV, UY);</li>\n      <li>Adex 200 (IL);</li>\n      <li>Adex Liqui-Gels (IL);</li>\n      <li>Advel (BD);</li>\n      <li>Advil (AU, BR, CO, EE, FR, HK, HU, IE, IL, LB, MX, PH, PL, RO, SA, VE, VN, ZA);</li>\n      <li>Afebril (EC, PY);</li>\n      <li>Aktren (AT);</li>\n      <li>Algofen (IT);</li>\n      <li>Am-Fam 400 (IN);</li>\n      <li>Anafen (ID);</li>\n      <li>Anco (DE);</li>\n      <li>Antarene (FR);</li>\n      <li>Arfen (ID);</li>\n      <li>Argifen (ES);</li>\n      <li>Asfen-400 (ET);</li>\n      <li>Balkaprofen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Bebyzal (KR);</li>\n      <li>Bestafen (MX);</li>\n      <li>Bifen (HK, SG);</li>\n      <li>Bofen (UA);</li>\n      <li>Brufen (AE, AT, AU, BD, BE, BH, CH, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IQ, IR, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, LY, MT, NL, NO, NZ, OM, PH, PK, PT, QA, RO, RU, SA, SE, SG, SI, SK, SY, TR, TW, VN, YE, ZA, ZW);</li>\n      <li>Brufen 400 (IL);</li>\n      <li>Brufen Forte (ID);</li>\n      <li>Brufen Retard (SG);</li>\n      <li>Brufen Syrup for Children (KR);</li>\n      <li>Brufort (IT);</li>\n      <li>Brupro (IE);</li>\n      <li>Bufect (ID, LK);</li>\n      <li>Bufect Forte (ID);</li>\n      <li>Buplex (IE);</li>\n      <li>Buprex (EC);</li>\n      <li>Burana (FI);</li>\n      <li>Butafen (ET);</li>\n      <li>Carol (KR);</li>\n      <li>Cefen (TH);</li>\n      <li>Cuprofen (TH);</li>\n      <li>Dafen-Q (KR);</li>\n      <li>Dalsy (ES);</li>\n      <li>Degiton (TW);</li>\n      <li>Diffutab SR 600 (KR);</li>\n      <li>Dolafen (PH);</li>\n      <li>Dolan FP (PH);</li>\n      <li>Dolex (ZW);</li>\n      <li>Dolgit (AE, BH, CY, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dolocyl (CH);</li>\n      <li>Dolomax (PE);</li>\n      <li>Doloral (PE);</li>\n      <li>Dolormin (DE);</li>\n      <li>Dolprin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Drin (GR);</li>\n      <li>Druisel (AR);</li>\n      <li>Easofen (MT);</li>\n      <li>Evofen (MY);</li>\n      <li>Expanfen (FR);</li>\n      <li>Extrapan Gel (HK);</li>\n      <li>Farsifen Forte (ID);</li>\n      <li>Febratic (MX);</li>\n      <li>Fenatic (ID);</li>\n      <li>Fenbid (AE, BF, BH, BJ, CI, CN, CY, EG, ET, GB, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Fenpaed (NZ);</li>\n      <li>Fever-Free (PH);</li>\n      <li>Flamex (BD);</li>\n      <li>Focus (IT);</li>\n      <li>Genofen (ET);</li>\n      <li>Gofen (LK, PH, TZ);</li>\n      <li>Gyno-neuralgin (DE);</li>\n      <li>Hagifen (VN);</li>\n      <li>Ibufac (MY);</li>\n      <li>Ibufen (IL, KR);</li>\n      <li>Ibuflam (MX);</li>\n      <li>Ibufug (DE);</li>\n      <li>Ibugesic (IN, LB, LK);</li>\n      <li>Ibulgan (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ibumetin (AT, DK, FI, NL, NO, SE);</li>\n      <li>Ibunorm (UA);</li>\n      <li>Ibupirac (AR, CL);</li>\n      <li>Ibuprofen (HK);</li>\n      <li>Ibusal (FI);</li>\n      <li>Ibuspan (ZW);</li>\n      <li>Imet (UA);</li>\n      <li>Infacalm (HK);</li>\n      <li>Inufen (ET);</li>\n      <li>Ipren (DK, RU, SE);</li>\n      <li>Iprox (ID);</li>\n      <li>Ipufen (TW);</li>\n      <li>Irfen (AE, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Junifen (ES);</li>\n      <li>Liptan (AE, BH, CY, EG, IL, IQ, IR, JO, JP, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Medicol (PH);</li>\n      <li>Medicol Advance (PH);</li>\n      <li>Mensoton (DE);</li>\n      <li>Mofen (ID);</li>\n      <li>Moris (ID);</li>\n      <li>Moris Forte (ID);</li>\n      <li>Motrin (AE, BH, CO, CR, CY, DO, EG, GT, HN, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PE, QA, SA, SV, SY, YE);</li>\n      <li>Mutrim (PH);</li>\n      <li>Neoprofen (BM);</li>\n      <li>Neutropain (HK);</li>\n      <li>Nobafon (TW);</li>\n      <li>Noritis (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Novogent (DE);</li>\n      <li>Nureflex (AT);</li>\n      <li>Nurofen (AT, AU, BE, BF, BG, BJ, CI, CY, CZ, DK, ES, ET, FR, GB, GH, GM, GN, HR, HU, IE, IS, KE, LR, LT, LU, LV, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, SC, SD, SE, SG, SI, SK, SL, SN, TN, TR, TZ, UG, VN, ZM, ZW);</li>\n      <li>Nurofen for Children (SG, TH);</li>\n      <li>Nurofen Gel (IL, NZ);</li>\n      <li>Nurofen Pro san sucre (FR);</li>\n      <li>Nuroffen (MT);</li>\n      <li>Nurosan (UA);</li>\n      <li>Optifen (CH);</li>\n      <li>Opturem (DE);</li>\n      <li>Ostarin (ID);</li>\n      <li>P-Fen (TH);</li>\n      <li>Panafen (NZ);</li>\n      <li>Pedea (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, KR, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Peflam (BD);</li>\n      <li>Perfen (TW);</li>\n      <li>Perofen (BB, BM, BS, BZ, GY, JM, SG, SR, TT);</li>\n      <li>Profen (BD, HK);</li>\n      <li>Profinal (AE, BH, KW, LB, MY, QA, SA);</li>\n      <li>Proris (ID);</li>\n      <li>Prosinal (ID);</li>\n      <li>Provon (PE);</li>\n      <li>Quadrax (MX);</li>\n      <li>Rafen (AU);</li>\n      <li>Ranofen (ZA);</li>\n      <li>RatioDolor (AT);</li>\n      <li>Remofen (AE, BH, JO, QA);</li>\n      <li>Rhelafen (ID);</li>\n      <li>Rhelafen Forte (ID);</li>\n      <li>Rheumanox (TH);</li>\n      <li>Rupan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ruprofen (TH);</li>\n      <li>Sapofen (AE, BH, JO, KW, QA, SA);</li>\n      <li>Spedifen (CN, FR);</li>\n      <li>Speedifen (TH);</li>\n      <li>Spifen (FR);</li>\n      <li>Syntofene (FR);</li>\n      <li>Tabalon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tabalon 400 (MX);</li>\n      <li>Tarein (TW);</li>\n      <li>Taskine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Tefin (IE);</li>\n      <li>Tenvalin (EC);</li>\n      <li>Thomaprodol (AT);</li>\n      <li>Ufen (LK);</li>\n      <li>Upfen (FR);</li>\n      <li>Uprofen (TW);</li>\n      <li>Urem (DE);</li>\n      <li>Vantril (PY);</li>\n      <li>Xfen Flashtab (PH);</li>\n      <li>Zofen (MY);</li>\n      <li>Zorafen (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amoozgar H, Ghodstehrani M, Pishva N. Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. <i>Pediatr Cardiol</i>. 2009 [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/19841966/pubmed\" target=\"_blank\" id=\"19841966\">19841966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amundsen S, Nordeng H, Nezvalov&aacute;-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. <i>Nat Rev Neurol</i>. 2015;11(4):209-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/25776823/pubmed\" target=\"_blank\" id=\"25776823\">25776823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranda JV, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. <i>Semin Perinatol</i>. 2006;30(3):114-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/16813969/pubmed\" target=\"_blank\" id=\"16813969\">16813969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. <i>Acta Paediatr</i>. 1997;86(3):289-293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/9099319/pubmed\" target=\"_blank\" id=\"9099319\">9099319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bellini C, Campone F, Serra G. Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. <i>CMAJ</i>. 2006; 174(13):1843-1844.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/16785458/pubmed\" target=\"_blank\" id=\"16785458\">16785458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde C, Ablin A, Glazer J, et al. American Academy of Pediatrics report of the subcommittee on disease-related pain in childhood cancer. <i>Pediatrics</i>. 1990; 86(5 Pt 2):818-825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/2216644/pubmed\" target=\"_blank\" id=\"2216644\">2216644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/12362012/pubmed\" target=\"_blank\" id=\"12362012\">12362012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/24663106/pubmed\" target=\"_blank\" id=\"24663106\">24663106</a>]</span><span class=\"doi\">10.1097/BOR.0000000000000054</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23558845/pubmed\" target=\"_blank\" id=\"23558845\">23558845</a>]</span><span class=\"doi\">10.1213/ANE.0b013e31828a4b54</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy PD. Changing the paradigm in pediatric acute kidney injury. <i>J Pediatr</i>. 2013;162(6):1094-1096.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23453549/pubmed\" target=\"_blank\" id=\"23453549\">23453549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caldolor (ibuprofen) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caldolor (ibuprofen) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capparelli EV. Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous ibuprofen lysine. <i>J Pediatr Pharmacol Ther</i>. 2007; 12:158-170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. <i>N Engl J Med</i>. 2001;45(25):1809-1817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/11752357/pubmed\" target=\"_blank\" id=\"11752357\">11752357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. <i>Clin Ther</i>. 2005;27(2):185-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/15811481/pubmed\" target=\"_blank\" id=\"15811481\">15811481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dani C, Vangi V, Bertini G, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. <i>Clin Pharmacol Ther</i>. 2012;91(4):590-596.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/22089267/pubmed\" target=\"_blank\" id=\"22089267\">22089267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. <i> J Clin Pharm Ther</i>. 2005;30(2):121-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/15811164/pubmed\" target=\"_blank\" id=\"15811164\">15811164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erdeve O, Gokmen T, Altug N, et al. Oral versus intravenous ibuprofen: which is better in closure of patent ductus arteriosus? <i>Pediatrics</i>. 2009;123(4):e763.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/19336363/pubmed\" target=\"_blank\" id=\"19336363\">19336363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2012;97(4):F279-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/22147286/pubmed\" target=\"_blank\" id=\"22147286\">22147286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gal P, Ransom JL, Davis SA. Possible ibuprofen-induced kernicterus in a near-term infant with moderate hyperbilirubinemia. <i>J Pediatr Pharmacol Ther</i>. 2006;11:245-250.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giannini EH, Brewer EJ, Miller ML, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. <i>J Pediatr</i>. 1990;117(4):645-652.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/2213396/pubmed\" target=\"_blank\" id=\"2213396\">2213396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gournay V, Savagner C, Thiriez G, et al. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. <i>Lancet</i>. 2002;359(9316):1486-1488.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/11988250/pubmed\" target=\"_blank\" id=\"11988250\">11988250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gregoire N, Gualano V, Geneteau A, et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. <i>J Clin Pharmacol</i>. 2004;44(10):1114-1124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/15342612/pubmed\" target=\"_blank\" id=\"15342612\">15342612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heyman E, Morag I, Batash D, et al. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. <i>Pediatrics</i>. 2003;112(5):e354.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/14595076/pubmed\" target=\"_blank\" id=\"14595076\">14595076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirt D, Van Overmeire B, Treluyer JM, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. <i>Br J Clin Pharmacol</i>. 2008;65(5):629-636.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/18307541/pubmed\" target=\"_blank\" id=\"18307541\">18307541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. <i>J Pediatr</i>. 1992;121(6):969-973.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/ 1447669 /pubmed\" target=\"_blank\" id=\" 1447669 \"> 1447669 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter Suppl</i>. 2013;3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. <i>N Engl J Med</i>. 1995;332(13):848-854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/7503838/pubmed\" target=\"_blank\" id=\"7503838\">7503838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konstan MW, Schluchter MD, Xue W, et al. Clinical use of Ibuprofen is associated with slower FEV<sub>1</sub> decline in children with cystic fibrosis. <i>Am J Respir Crit Care Med</i>. 2007;176(11):1084-1089.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/17872492/pubmed\" target=\"_blank\" id=\"17872492\">17872492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. <i>Eur J Pediatr</i>. 2002;161(4):202-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/12014386/pubmed\" target=\"_blank\" id=\"12014386\">12014386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CH, Chen HN, Tsao LY, et al. Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants. <i>Pediatr Neonatol</i>. 2012;53(6):346-353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23276438/pubmed\" target=\"_blank\" id=\"23276438\">23276438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. <i>JAMA</i>. 1995;273(12):929-933.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/7884951/pubmed\" target=\"_blank\" id=\"7884951\">7884951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lesko SM, Mitchell A. The safety of acetaminophen and ibuprofen among children younger than two years old. <i>Pediatrics</i>. 1999;104(4). Available at: <a href=\"http://www.fda.gov/cder/drug/advisory/codeine.htm\" target=\"_blank\">http://www.fda.gov/cder/drug/advisory/codeine.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/10506264 /pubmed\" target=\"_blank\" id=\"10506264 \">10506264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. <i>Paediatr Drugs</i>. 2001;3(11):817-858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/11735667/pubmed\" target=\"_blank\" id=\"11735667\">11735667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/24927294/pubmed\" target=\"_blank\" id=\"24927294\">24927294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchei E, Pellegrini M, Pichini S, et al, &ldquo;Are False-Positive Phencyclidine Immunoassay Instant-View Multi-Test Results Caused by Overdose Concentrations of Ibuprofen, Metamizol, and Dextromethorphan?&rdquo; <i>Ther Drug Monit</i>, 2007, 29(5):671-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/17898664/pubmed\" target=\"_blank\" id=\"17898664\">17898664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayoral CE, Marino RV, Rosenfeld, W, et al. Alternating antipyretics: is this an alternative? <i>Pediatrics</i>. 2000;105(5):1009-1012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/10790455/pubmed\" target=\"_blank\" id=\"10790455\">10790455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mei&szlig;ner U, Chakrabarty R, Topf HG, et al. Improved closure of patent ductus arteriosus with high doses of ibuprofen. <i>Pediatr Cardiol</i>. 2012;33(4):586-590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/22307401/pubmed\" target=\"_blank\" id=\"22307401\">22307401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misurac JM, Knoderer CA, Leiser JD, et al. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. <i>J Pediatr</i>. 2013;162(6):1153-1159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23360563/pubmed\" target=\"_blank\" id=\"23360563\">23360563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23540878/pubmed\" target=\"_blank\" id=\"23540878\">23540878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motrin (ibuprofen) [prescribing information]. Fort Washington, PA: McNeil Healthcare LLC;</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants (review). <i>Cochrane Database Syst Rev</i>. 2011;7:CD00421.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. <i>Cochrane Database Syst Rev</i>. 2013;(4):CD003481.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23633310/pubmed\" target=\"_blank\" id=\"23633310\">23633310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pai VB, Sakadjian A, Puthoff TD. Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus. <i>Pharmacotherapy</i>. 2008;28(9):1162-1182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/18752387/pubmed\" target=\"_blank\" id=\"18752387\">18752387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&quot; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rigourd V, de Villepin B, Amirouche A, et al. Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 &quot;Antalait&quot; study. <i>Ther Drug Monit</i>. 2014;36(5):590-596.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/24695355 /pubmed\" target=\"_blank\" id=\"24695355 \">24695355 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rollins DE, Jennison TA, and Jones G, &ldquo;Investigation of Interference by Nonsteroidal Anti-Inflammatory Drugs in Urine Tests for Abused Drugs,&rdquo; <i>Clin Chem</i>, 1990, 36(4):602-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/2323039/pubmed\" target=\"_blank\" id=\"2323039\">2323039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saavedra Salinas M&Aacute;, Barrera Cruz A, Cabral Casta&ntilde;eda AR, et al. Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II. <i>Reumatol Clin</i>. 2015;11(5):305-315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/25683368/pubmed\" target=\"_blank\" id=\"25683368\">25683368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. <i>Curr Opin Rheumatol</i>. 2014;26(3):354-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/24614280 /pubmed\" target=\"_blank\" id=\"24614280 \">24614280 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott CS, Retsch-Bogart GZ, Kustra RP, et al. The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. <i>J Pediatr</i>. 1999;134(1):58-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/9880450/pubmed\" target=\"_blank\" id=\"9880450\">9880450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sullivan JE, Farrar HC, et al. Fever and antipyretic use in children. <i>Pediatrics</i>. 2011;127(3):580-587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/21357332/pubmed\" target=\"_blank\" id=\"21357332\">21357332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Overmeire B. Common clinical and practical questions on the use of intravenous ibuprofen lysine for the treatment of patent ductus arteriosus. <i>J Pediatr Pharmacol Ther</i>. 2007;12:194-206.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. <i>N Engl J Med</i>. 2000;343(10):674-681.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/10974130/pubmed\" target=\"_blank\" id=\"10974130\">10974130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Overmeire B, Touw D, Schepens PJ, et al. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. <i>Clin Pharmacol Ther</i>. 2001;70(4):336-343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/11673749/pubmed\" target=\"_blank\" id=\"11673749\">11673749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walter K and Dilger C, &quot;Ibuprofen in Human Milk,&quot; <i>Br J Clin Pharmacol</i>. 1997; 44(2):211-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/9278216/pubmed\" target=\"_blank\" id=\"9278216\">9278216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13371 Version 294.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708913\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181456\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181457\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053332\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442611\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053326\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181430\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F181416\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23884416\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874617\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053337\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2985480\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053336\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181516\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181514\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181438\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181420\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023241\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F181500\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181425\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F181452\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7684272\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053331\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1053335\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181419\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F181437\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1053342\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181440\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181443\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13371|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">Ibuprofen: Drug information</a></li><li><a href=\"topic.htm?path=ibuprofen-patient-drug-information\" class=\"drug drug_patient\">Ibuprofen: Patient drug information</a></li></ul></div></div>","javascript":null}